The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Impact of ASXL1 mutations in favorable risk AML treated with ven-containing low-intensity therapy
Jennifer Marvin-Peek, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the association of ASXL1 mutations with adverse outcomes in patients with European LeukemiaNet (ELN) 2024 favorable-risk acute myeloid leukemia (AML) treated with venetoclax (ven)-containing low-intensity therapy. Dr Marvin-Peek highlights that ASXL1 mutations are associated with lower response rates, poorer relapse-free survival, and overall survival, resembling intermediate-risk disease. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
